Initiative for Medicines, Access & Knowledge
@imakglobal.bsky.social
We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.
Pinned
🚨NEW: Today we published a new Overpatented, Overpriced report and launched an expanded and updated version of The Drug Patent Book, our searchable database of every patent we've uncovered on many of the most widely-used drugs in the U.S.
Medicare's Drug Price Negotiation Program recently announced the 15 drugs selected for its third round of negotiations. As the program expands, its success is in danger of being undercut by legislators giving drug companies new ways to extend their monopolies. 🧵
www.statnews.com/2026/01/27/m...
www.statnews.com/2026/01/27/m...
15 new drugs added to Medicare price negotiations
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices.
www.statnews.com
February 4, 2026 at 3:34 PM
Medicare's Drug Price Negotiation Program recently announced the 15 drugs selected for its third round of negotiations. As the program expands, its success is in danger of being undercut by legislators giving drug companies new ways to extend their monopolies. 🧵
www.statnews.com/2026/01/27/m...
www.statnews.com/2026/01/27/m...
NEWS: @tahiramin.bsky.social and Rohit Malpani are releasing a new book! 📚
In it, they examine the origins of a global public health system that protects pharmaceutical monopolies instead of the public interest and people’s lives.
In it, they examine the origins of a global public health system that protects pharmaceutical monopolies instead of the public interest and people’s lives.
I’m excited to share that my first book, Pharma Monopoly: The Battle for the Future of Medicines, co-written with Rohit Malpani, will be published in March in the UK/Europe and May in the U.S.
January 22, 2026 at 12:13 AM
NEWS: @tahiramin.bsky.social and Rohit Malpani are releasing a new book! 📚
In it, they examine the origins of a global public health system that protects pharmaceutical monopolies instead of the public interest and people’s lives.
In it, they examine the origins of a global public health system that protects pharmaceutical monopolies instead of the public interest and people’s lives.
Reposted by Initiative for Medicines, Access & Knowledge
This is called product hopping.
January 15, 2026 at 5:05 PM
This is called product hopping.
We will be closely watching how Eli Lilly and Novo Nordisk adapt their patenting schemes to maintain monopoly control and delay affordable options for the GLP-1 market.
www.law360.com/classaction/...
www.law360.com/classaction/...
Drugmakers Fight Multifront Legal Battles Over GLP-1s - Law360
In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitor...
www.law360.com
January 12, 2026 at 1:47 PM
We will be closely watching how Eli Lilly and Novo Nordisk adapt their patenting schemes to maintain monopoly control and delay affordable options for the GLP-1 market.
www.law360.com/classaction/...
www.law360.com/classaction/...
We mourn the loss of David Mitchell, founder of Patients For Affordable Drugs (@p4ad.bsky.social).
David showed the world that even when systems feel too big and entrenched to challenge, they are not beyond our collective power.
David showed the world that even when systems feel too big and entrenched to challenge, they are not beyond our collective power.
January 8, 2026 at 3:18 PM
We mourn the loss of David Mitchell, founder of Patients For Affordable Drugs (@p4ad.bsky.social).
David showed the world that even when systems feel too big and entrenched to challenge, they are not beyond our collective power.
David showed the world that even when systems feel too big and entrenched to challenge, they are not beyond our collective power.
In 2025, we won some hard-fought victories in the fight for patent reform. Yet despite this progress, our year-in-review newsletter must focus on something deeply troubling: the hollowing out of the United States Patent and Trademark Office.
mailchi.mp/i-mak/how-th...
mailchi.mp/i-mak/how-th...
How the USPTO was Hollowed Out in 2025
Despite some hard-fought victories in the fight for patent reform, our year-in-review newsletter must focus on something deeply troubling.
mailchi.mp
December 19, 2025 at 6:35 PM
In 2025, we won some hard-fought victories in the fight for patent reform. Yet despite this progress, our year-in-review newsletter must focus on something deeply troubling: the hollowing out of the United States Patent and Trademark Office.
mailchi.mp/i-mak/how-th...
mailchi.mp/i-mak/how-th...
NEW: Read our account detailing how a small group of policymakers—incl. USPTO Director John Squires, Acting USPTO Director Coke Morgan-Stewart, Senators Tillis and Coons, and former USPTO Director Andrei Iancu—pushed industry-backed efforts to hollow out the USPTO.
🔗 www.i-mak.org/2025/12/16/h...
🔗 www.i-mak.org/2025/12/16/h...
December 19, 2025 at 6:30 PM
NEW: Read our account detailing how a small group of policymakers—incl. USPTO Director John Squires, Acting USPTO Director Coke Morgan-Stewart, Senators Tillis and Coons, and former USPTO Director Andrei Iancu—pushed industry-backed efforts to hollow out the USPTO.
🔗 www.i-mak.org/2025/12/16/h...
🔗 www.i-mak.org/2025/12/16/h...
👏 NEWS: Teva removes over 200 improper Orange Book patent listings under pressure from the FTC.
🔗 www.fiercepharma.com/pharma/ftc-c...
🔗 www.fiercepharma.com/pharma/ftc-c...
December 11, 2025 at 8:31 PM
👏 NEWS: Teva removes over 200 improper Orange Book patent listings under pressure from the FTC.
🔗 www.fiercepharma.com/pharma/ftc-c...
🔗 www.fiercepharma.com/pharma/ftc-c...
“Patent reform is our best path forward for addressing a root cause of high drug prices in a bipartisan manner.” @tahiramin.bsky.social
www.statnews.com/sponsor/2025...
www.statnews.com/sponsor/2025...
Four in five Americans support patent reform to lower drug prices, new survey finds
A new national survey reveals overwhelming bipartisan support for overhauling the patent system to address soaring prescription drug costs in the United
www.statnews.com
December 5, 2025 at 2:53 PM
“Patent reform is our best path forward for addressing a root cause of high drug prices in a bipartisan manner.” @tahiramin.bsky.social
www.statnews.com/sponsor/2025...
www.statnews.com/sponsor/2025...
Reposted by Initiative for Medicines, Access & Knowledge
This is true. Look at AbbVie’s CEO. It says a lot about a pharma company's priorities when their CEO's bio focuses entirely on financial achievements.
December 4, 2025 at 2:54 PM
This is true. Look at AbbVie’s CEO. It says a lot about a pharma company's priorities when their CEO's bio focuses entirely on financial achievements.
SENATOR WELCH: Pharmaceutical companies used to be run by scientists. They’re now run by MBAs.
December 4, 2025 at 2:52 PM
SENATOR WELCH: Pharmaceutical companies used to be run by scientists. They’re now run by MBAs.
During our recent webinar, @tahiramin.bsky.social, @welch.senate.gov, and @emilypisacreta.bsky.social looked back at a 2019 exchange between Sen. John Cornyn and former AbbVie CEO Richard Gonzalez, in which Gonzalez openly admitted to stockpiling hundreds of patents on Humira.
December 3, 2025 at 11:19 PM
During our recent webinar, @tahiramin.bsky.social, @welch.senate.gov, and @emilypisacreta.bsky.social looked back at a 2019 exchange between Sen. John Cornyn and former AbbVie CEO Richard Gonzalez, in which Gonzalez openly admitted to stockpiling hundreds of patents on Humira.
NEW: We partnered with @statnews.com to analyze findings from a national @fandmpoll.bsky.social survey we commissioned to understand the public’s top concerns on drug pricing.
www.statnews.com/sponsor/2025...
www.statnews.com/sponsor/2025...
Four in five Americans support patent reform to lower drug prices, new survey finds
A new national survey reveals overwhelming bipartisan support for overhauling the patent system to address soaring prescription drug costs in the United
www.statnews.com
December 2, 2025 at 10:37 PM
NEW: We partnered with @statnews.com to analyze findings from a national @fandmpoll.bsky.social survey we commissioned to understand the public’s top concerns on drug pricing.
www.statnews.com/sponsor/2025...
www.statnews.com/sponsor/2025...
Reposted by Initiative for Medicines, Access & Knowledge
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
November 19, 2025 at 3:10 PM
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
November 15, 2025 at 5:22 PM
NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.
Read the interview: www.mlex.com/mlex/article...
Read the interview: www.mlex.com/mlex/article...
In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College.
www.i-mak.org/2025/11/10/n...
www.i-mak.org/2025/11/10/n...
New survey shows Americans want patent reform
Building a more just and equitable medicines system for all
www.i-mak.org
November 10, 2025 at 8:41 PM
In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College.
www.i-mak.org/2025/11/10/n...
www.i-mak.org/2025/11/10/n...
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
October 27, 2025 at 11:09 PM
Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
October 27, 2025 at 11:05 PM
Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
October 27, 2025 at 11:04 PM
Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.
Reposted by Initiative for Medicines, Access & Knowledge
TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits.
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
TrumpRx and a most favored nation policy won’t lower prices for patients
TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.
www.statnews.com
October 27, 2025 at 9:57 PM
TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits.
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...
Reposted by Initiative for Medicines, Access & Knowledge
Thank to our colleagues of @imakglobal.bsky.social
for this strong analyse : www.statnews.com/2025/10/24/t...
for this strong analyse : www.statnews.com/2025/10/24/t...
TrumpRx and a most favored nation policy won’t lower prices for patients
TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.
www.statnews.com
October 27, 2025 at 10:10 PM
Thank to our colleagues of @imakglobal.bsky.social
for this strong analyse : www.statnews.com/2025/10/24/t...
for this strong analyse : www.statnews.com/2025/10/24/t...
🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel.
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
www.nytimes.com
October 24, 2025 at 1:17 PM
🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel.
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social
www.nytimes.com/2025/10/23/h...
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
October 22, 2025 at 3:40 PM
🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.
🔗 www.statnews.com/pharmalot/20...
🔗 www.statnews.com/pharmalot/20...
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
October 22, 2025 at 1:05 PM
⏰ Our webinar is starting in 1 hour!
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.
Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention?
www.i-mak.org/2025/10/17/k...
www.i-mak.org/2025/10/17/k...
Keytruda Qlex: Where’s the invention?
Building a more just and equitable medicines system for all
www.i-mak.org
October 21, 2025 at 3:50 PM
In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention?
www.i-mak.org/2025/10/17/k...
www.i-mak.org/2025/10/17/k...